Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
Abstract Background and Aims Semaglutide has been studied in patients with metabolic dysfunction‐associated steatohepatitis (MASH) due to potential benefit from weight loss on liver inflammation. However, preclinical studies suggest that MASH improvement may be independent of weight loss. We aim to...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.13037 |